DANOCRINE
LOE ApproachingNDAORALCAPSULEPriority Review
Approved
Jun 1976
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
DANOCRINE (danazol) is an oral small-molecule androgenic agent approved in 1976 for rare endocrine and hematologic conditions. The exact indications are not specified in available data, but the drug is used in specialty care settings. Its mechanism involves androgen receptor modulation and suppression of gonadotropins.
LOE Approaching
With LOE approaching and no active genericization data provided, this mature product likely operates with a small, lean team focused on managed decline and specialty market retention.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
DANOCRINE presents a niche career opportunity suited to professionals with specialty pharma experience and interest in lifecycle management rather than launch innovation. The zero linked job count and LOE-approaching status indicate a stable but contracting organization with limited entry points.
Product ManagerMarket Access Specialist
Worked on DANOCRINE at Sanofi? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.